Insilico and Tenacia expand AI CNS pact to $94.75 million
CURRENT FULL VERSION: Insilico Medicine is widening its neuroscience push with an expanded collaboration with Tenacia Biotechnology worth up to $94.75 million, the companies announced March 26, 2026. The new agreement adds another AI-driven CNS discovery program, building on a partnership the companies began in March 2025 and underscoring how Insilico is using repeat collaborations to validate its generative drug discovery model. (prnewswire.com)
The background here is important. The original Insilico-Tenacia alliance centered on discovering small molecules for CNS disease with strong blood-brain barrier permeability, one of the core technical hurdles in neurology drug development. According to the companies, that first program has progressed smoothly enough over the past year to support a deeper commitment. Tenacia, founded in 2022 by Bain Capital and focused on underserved neurological disorders, brings CNS specialization and regional development ambition, while Insilico contributes its Pharma.AI discovery platform and internal drug design capabilities. (prnewswire.com)
Under the expanded pact, the companies plan to jointly develop an additional candidate with defined properties for challenging neurological diseases and move it to the preclinical candidate stage. Insilico said it is eligible for near-term and milestone payments under the deal, which carries total additional potential value of up to $94.75 million. The announcement did not identify the target, but it did emphasize that this is effectively a second program around the same target with differentiated attributes, suggesting the partners are trying to build optionality early rather than rely on a single chemistry path. (prnewswire.com)
Insilico framed the move as part of a broader CNS and partnering strategy. In January 2026, it announced a separate co-development and licensing deal with Hygtia Therapeutics around ISM8969, a brain-penetrant NLRP3 inhibitor for CNS disease, with milestone value reported at more than HK$500 million, or about $66 million in coverage of the deal. Insilico has also been attracting bigger pharma attention: this week, PharmaShots reported that Eli Lilly signed a separate multi-program AI-driven collaboration with Insilico worth up to $2.75 billion. Under that agreement, Lilly is set to pay $115 million upfront, gain exclusive global rights to develop, manufacture, and commercialize Insilico’s preclinical oral candidates for select indications, and work with Insilico on multiple R&D programs focused on Lilly-selected targets using Pharma.AI. Insilico would also be eligible for development, regulatory, and commercial milestones plus tiered royalties on future sales. Taken together, those deals suggest the company is increasingly being valued not just for a single asset, but for its ability to repeatedly generate partnerable programs. (biopharmatrend.com; PharmaShots)
The clearest executive reaction came from Insilico founder and CEO Alex Zhavoronkov, who said launching a second program with differentiated attributes for the same target in a short time shows the “depth and flexibility” of generative AI in drug design. Tenacia said the initial collaboration had already demonstrated the value of combining the two companies’ expertise. Those are expected statements in a company release, but they align with a wider industry pattern: partners appear increasingly willing to structure AI collaborations around multiple shots on goal, especially in areas like CNS where attrition risk is high and differentiated molecular profiles matter. The Lilly deal adds another layer to that pattern because it is not just a single-asset bet; it is structured around multiple therapeutic areas and multiple Lilly-selected targets, with exclusive downstream rights for Lilly on certain candidates. That final point is an inference based on the structure of these deals and Insilico’s recent partnering activity. (prnewswire.com; PharmaShots)
Why it matters: For veterinary professionals, the direct commercial impact is limited today, because this is a human CNS discovery partnership. Still, the strategic signal matters. AI-enabled discovery platforms are increasingly being judged by whether they can repeatedly generate viable programs, attract milestone-based partners, and move candidates into preclinical or clinical development. Insilico has explicitly said its platform extends beyond human therapeutics into veterinary medicine, agriculture, and nutrition, so each new deal adds to the evidence base that platform-style R&D could influence how future animal health products are identified and prioritized. The added detail from the Lilly agreement matters here too: a large pharma company was willing to commit meaningful upfront capital and a multi-program structure around Pharma.AI, which is a stronger validation signal than a one-off exploratory collaboration. For veterinary industry watchers, this is less about one neurology asset and more about the normalization of AI as infrastructure for drug discovery. (prnewswire.com; PharmaShots)
There’s also a financing and market context. Insilico listed on the Hong Kong Stock Exchange on December 30, 2025, in what multiple sources described as Hong Kong’s largest biotech IPO of 2025. Since then, the company has kept a steady cadence of collaborations and pipeline updates, which helps explain why partners may be more comfortable expanding existing relationships rather than starting from scratch. In other words, Tenacia’s follow-on commitment may matter as much as the headline dollar figure, because repeat business is one of the more credible external validations an AI drug discovery company can get. That point looks even stronger when placed alongside a $2.75 billion multi-program Lilly alliance with $115 million upfront and royalty economics, because it shows validation coming from both an existing specialist partner and a major global pharma company. That last point is an inference from the company’s post-IPO deal flow and this expansion. (prnewswire.com; PharmaShots)
What to watch: The next markers will be whether the companies disclose the biological target, when they expect to nominate a preclinical candidate, and whether this collaboration produces data strong enough to support IND-enabling work or a broader regional licensing structure. Veterinary professionals tracking translational innovation should also watch whether Insilico begins talking more concretely about animal health applications, since the company already names veterinary medicine as one of the sectors where its platform could be applied. More broadly, watch whether Insilico’s newer large-scale alliances, including the Lilly collaboration, translate into named targets, candidate nominations, or downstream development milestones rather than staying at the platform-validation stage. (prnewswire.com; PharmaShots)